drugset
drugset / Trial / NCT03884829

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

NCT03884829 ↗

Phase 1 Terminated 7 enrolled Cyclacel Pharmaceuticals, Inc. M.D. Anderson Cancer Center · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes

Timeline

Start
2019-03-25
Primary completion
2021-11-29
Completion
2023-10-19

Outcome

Outcome not reported

Stopped: “Switch to oral formulation of CYC140 (plogosertib)”

Drugs

EvaluationDrugModalityDoseRoute
Subject CYC140 Unknown — Other

Indications

B-cell chronic lymphocytic leukemia acute myeloid leukemia adult acute lymphoblastic leukemia chronic myeloid leukemia myelodysplastic syndrome